C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for detecting and treating early-stage Alzheimer's disease as well as other inflammatory neurologic conditions.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
16 - Paper, cardboard and goods made from these materials
24 - Textiles and textile goods
25 - Clothing; footwear; headgear
28 - Games; toys; sports equipment
41 - Education, entertainment, sporting and cultural services
Goods & Services
Paper products, namely, stationery, note pads, napkins, bumper stickers, notebooks, pocketed folders, binders, souvenir programs concerning athletic events and educational speakers, newsletters in the field of educational matters, decals, calendars, greeting cards, post cards, note cards, day planners, and gift bags; pens; pencils, erasers; temporary tattoos; plastic bags for packaging; signs; paper banners; paper flags; graphic and printed art reproductions banners and flags of textile; plastic flags; textile banners; towels; pennants of textile; fleece blankets; blanket throws Clothing, namely, t-shirts, sweatshirts, shirts, pants, jackets, shorts, vests, jerseys, neckties, bowties, socks, aprons, bibs not of paper, underwear, rainwear, belts, scarves, swimwear, tank tops, dresses, skirts, rompers, pajamas, sweaters, headbands, gloves; hats; footwear puzzles; foam products; cheerleading pom-poms; golf divot repair tools; golf ball markers; golf bags; golf balls; novelty replica sports helmet Educational and entertainment services, namely, providing courses of instruction at the college level, offering a wide array of intercollegiate sports exhibitions, and producing radio and television programs; entertainment services in the nature of a wide array of intercollegiate sporting competitions and sporting events, and organizing cultural events
4.
METHOD OF TREATING POLYAMINE IMBALANCE-RELATED DISORDERS
The disclosure provides a method of treating a polyamine imbalance-related disorder. The method comprises administering phenylbutyrate to a subject in need thereof, thereby treating the polyamine imbalance-related disorder.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
5.
ENGINEERED MEGANUCLEASES THAT TARGET HUMAN MITOCHONDRIAL GENOMES
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.
The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for detecting and treating early-stage Alzheimer's disease as well as other inflammatory neurologic conditions.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
The present disclosure, relates, in general to analogs of proline-rich polypeptide 1 (PRP-1) designated tyrosine peptides (TYR peptide) that are useful to treat cancer, such as sarcomas, carcinomas and leukemias or liquid cancers.
An array of inflammatory cytokines are useful as a biomarker of traumatic brain injury, including inflammasome proteins. Biomarker cut-off points, ROC, and other characteristics have been determined.
The present disclosure relates, in general, to methods for the modulation of a target gene expression by the combined use of nucleic acid based therapeutics targeting complementary gene regulation mechanisms (upNA), leading to desired effects in excess of sum of the effects of each treatment alone, as well as the use of the combinations for the treatment of genetic (e.g., neurological) diseases and disorders associated with aberrant expression of the target gene(s).
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
10.
COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS AND ALLEVIATING FATIGUE
The present disclosure is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, and to administering gene therapy to the subject by introducing normal human MCT8 into the subject's cells in order to increase T3 in the subject's brain.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 5/14 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
The present disclosure is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a pregnant mother of a prenatal subject in need thereof, and to pharmaceutical DIPTA formulations for administration to the pregnant mother of a prenatal subject in need thereof.
The present subject matter is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, wherein the DITPA administration reduces triiodothyronine ("T3") serum levels to normal, increases T3 brain levels to normal, and maintains normal serum levels of thyroxine (T4) and thyroid stimulating hormone (TSH). The subject may be a child or an adult.
The present disclosure is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, and to administering gene therapy to the subject by introducing normal human MCT8 into the subject's cells in order to increase T3 in the subject's brain.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61P 25/00 - Drugs for disorders of the nervous system
15.
METHODS AND FORMULATIONS FOR PRENATAL TREATMENT OF ALLAN-HERNDON-DUDLEY SYNDROME
The present disclosure is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a pregnant mother of a prenatal subject in need thereof, and to pharmaceutical DIPTA formulations for administration to the pregnant mother of a prenatal subject in need thereof.
The present subject matter is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, wherein the DITPA administration reduces triiodothyronine (“T3”) serum levels to normal, increases T3 brain levels to normal, and maintains normal serum levels of thyroxine (T4) and thyroid stimulating hormone (TSH). The subject may be a child or an adult.
Cannabinoids are a promising and potent class of agents in the management of pain, and preclinical studies in rodent models suggest that cannabinoids may be particularly potent in relieving neuropathic pain. Despite the potential benefits and value of cannabinoids, clinical acceptance has been limited due to CNS side effects at systemic analgesic doses and the fear of misuse potential. What is needed are novel cannabinoid-acting compositions and methods for treating pain. The present disclosure relates to compositions targeting cannabinoid receptors and uses thereof for treating, preventing, and/or mitigating pain.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure relates to recombinant polypeptides and uses thereof for treating, preventing, and detecting inflammatory diseases. Specifically, the disclosure provides a recombinant polypeptide comprising an IL-2 polypeptide, a CD25 polypeptide, and an IL- 10 polypeptide, wherein the CD25 polypeptide comprises an extracellular domain of a CD25 protein. In some embodiments, the IL-10 polypeptide is linked to the C-terminus of the CD25 polypeptide.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
C07K 1/00 - General processes for the preparation of peptides
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A pharmaceutical composition for use in preventing or treating graft versus host disease (GVHD) in a subject wherein the composition includes intact microvesicles isolated from a biological fluid using polyethylene glycol (PEG) precipitation, wherein administration of the pharmaceutical composition alleviates or prevents one or more symptoms of GVHD in the subject. Also described is a method of preventing or treating graft versus host disease (GVHD) in a subject comprising administering to the subject a pharmaceutical composition comprising intact microvesicles isolated from a biological fluid of an unrelated or related donor using polyethylene glycol (PEG) precipitation wherein one or more symptoms of GVHD comprising weight loss, cutaneous tissue damage, subcutaneous tissue damage, cutaneous inflammation, satellite cell necrosis, truncated lifespan, and/or subcutaneous inflammation are prevented or alleviated in the subject.
Provided herein are small molecule inhibitors of coronavirus attachment and entry, related pharmaceutical compositions, uses, and methods thereof, wherein the compound has a structure of Formula (I):
Provided herein are small molecule inhibitors of coronavirus attachment and entry, related pharmaceutical compositions, uses, and methods thereof, wherein the compound has a structure of Formula (I):
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
Method to measure a visual photosensitivity discomfort threshold or presence of a condition associated therewith within a subject, includes obtaining, by one or more processors, a plurality of images of the subject captured while the at least one pupil and corresponding palpebral fissure contour was being subjected to a light stimuli; determining, by the one or more processors, executing instructions for a neural network having been trained using a plurality of images of a plurality of subjects captured at a plurality of different illumination levels, an output value corresponding to a measure of visual photosensitivity discomfort threshold in which the visual photosensitivity discomfort threshold is defined by an estimated illuminance of the retina of the subject, and outputting, by the one or more processors, the output value in a report.
A61B 3/06 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing colour vision
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
A61B 3/14 - Arrangements specially adapted for eye photography
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
23.
METHOD FOR ISOLATION AND PURIFICATION OF MICROVESICLES FROM CELL CULTURE SUPERNATANTS AND BIOLOGICAL FLUIDS
The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tis -sue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and/or mobility, or alter normal cell growth and/or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.
A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
A61K 35/22 - Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
Disclosed herein are biocompatible and biodegradable nanomaterials combined with molecules of interest and stem cells in a variety of stable and safe compositions. The nanomaterials comprise poly(ethylene glycol)-oligo(ethylene sulfide) (PEG-OES) amphiphilic block-copolymers that self-assemble in supramolecular aggregates of fibrillar shape. The fibrillar architecture of the assemblies allows the easy, fast and not harmful internalization into stem cells, including the preferred umbilical cord derived mesenchymal stem cells (UC-MSC). The OES core enables loading of hydrophobic molecules, such as imaging agents and drugs, which are carried by the nFIB into the stem cells for a final product that comprises a composition of MSC, nFIB and therapeutic molecule (e.g., MSC-nFIB-Rapamycin). The technology can be utilized to enhance the immunoregulatory potency of MSC via intracellular nanomaterial delivery of immunosuppressive drugs, and to obtain active site-targeting and localized delivery of drug-loaded nanofibrils by exploiting the MSC homing ability.
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
25.
THERAPEUTIC COMPOSITIONS FOR SKIN DISORDERS AND WOUND REPAIR
Disclosed herein are therapeutics compositions including one or more active agents, for instance a statin, cyclodextrin, or combination thereof. The compositions are useful in the treatment of tissue injuries, including wounds, as well as skin inflammation and infections.
A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
A61K 49/18 - Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
26.
INNATE IMMUNE PROTEINS AS BIOMARKERS FOR CNS INJURY
The present invention provides novel markers of the severity of a central nervous system injury, such as spinal cord injury or traumatic brain injury, in a patient. In particular, protein components of inflammasomes in the cerebrospinal fluid that can be used to assess the severity of central nervous system injury in a patient are disclosed. Methods of using such protein biomarkers to determine a prognosis, direct treatment and rehabilitation efforts, and monitor response to treatment for a patient with a central nervous system injury are also described.
Disclosed herein are novel compounds with STK17A inhibitory activity. The compounds may be used to treat proliferative disorders, including myelodysplastic syndrome and leukemia.
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
An array of inflammatory cytokines are useful as a biomarker useful for detection, diagnosis, and treatment of traumatic brain injury, Inflammatory cytokine cut-off values or cut-off points, ROC, and other characteristics have been determined.
A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
In certain embodiments, double-vision-related vision defects determinations or modifications may be facilitated. In some embodiments, a stimulus may be to be presented at a first time at a position on a first display for a deviating eye of a user (e.g., without a stimulus being presented on a second display of for a reference eye of the user) to cause the deviating eye to fixate on the position on the first display. A deviation measurement for the deviating eye may be determined based on an amount of movement of the deviating eye occurring upon the presentation on the first display for the deviating eye at the first time. In some embodiments, a modification profile associated with the user may be determined based on the deviation measurement, where the modification profile includes one or more modification parameters to be applied to modify an image for the user.
A61B 3/028 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determination of refraction, e.g. phoropters
H04N 9/64 - Circuits for processing colour signals
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
A61B 3/14 - Arrangements specially adapted for eye photography
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
G06V 20/20 - Scenes; Scene-specific elements in augmented reality scenes
G06V 40/18 - Eye characteristics, e.g. of the iris
G06F 18/214 - Generating training patterns; Bootstrap methods, e.g. bagging or boosting
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/774 - Generating sets of training patterns; Bootstrap methods, e.g. bagging or boosting
A pharmaceutical composition for use in preventing or treating graft versus host disease (GVHD) in a subject wherein the composition includes intact microvesicles isolated from a biological fluid using polyethylene glycol (PEG) precipitation, wherein administration of the pharmaceutical composition alleviates or prevents one or more symptoms of GVHD in the subject. Also described is a method of preventing or treating graft versus host disease (GVHD) in a subject comprising administering to the subject a pharmaceutical composition comprising intact microvesicles isolated from a biological fluid of an unrelated or related donor using polyethylene glycol (PEG) precipitation wherein one or more symptoms of GVHD comprising weight loss, cutaneous tissue damage, subcutaneous tissue damage, cutaneous inflammation, satellite cell necrosis, truncated lifespan, and/or subcutaneous inflammation are prevented or alleviated in the subject.
UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
UNIVERSITY OF MIAMI (USA)
Inventor
Goldhagen, Brian
Abstract
Methods, systems, and apparatuses are provided for retinal distance-screening using machine learning. Technologies disclosed herein, individually or in combination, provide a sensitive screening tool that utilizes machine learning to identify ocular abnormalities in retinal photos, differentiating normal fundus photos from abnormal fundus photos. Examples of ocular abnormalities that can be identified include diabetic retinopathy, macular degeneration, and glaucoma. Technologies disclosed herein, individually or in combination, can be used as a retinal distance-screening product or can be integrated into existing retinal distance-screening platforms. In some implementations, a list of patients can be obtained, retinal images pertaining to the patients in the list can be designated as either normal or abnormal, and results of such classification can be supplied for further analysis. The technologies described herein can be implemented to pre-screen patients into those that need further assessment by our trained optometrists and those that do not need further assessment.
G06T 5/50 - Image enhancement or restoration by the use of more than one image, e.g. averaging, subtraction
G06T 7/37 - Determination of transform parameters for the alignment of images, i.e. image registration using transform domain methods
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
34.
Engineered meganucleases that target human mitochondrial genomes
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/473 - Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 31/499 - Spiro-condensed pyrazines or piperazines
A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/66 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
36.
SYSTEM AND METHOD FOR CONCURRENT ENCRYPTION AND LOSSLESS COMPRESSION OF DATA
The Research Foundation for the State University of New York (USA)
University of Miami (USA)
Stetson University (USA)
Inventor
Arnavut, Ziya
Koc, Basar
Koçak, Hüseyin
Abstract
A system and method for concurrent encryption and lossless compression of data with an algorithm executing on a computer platform. The lossless compression component of the algorithm consists of preprocessing the data with a Burrows-Wheeler transformation followed by an inversion ranking transformation in advance of employing an entropy coder, such as binary arithmetic coder. The frequency vector of the Inversion Ranking transformation is then encrypted and transmitted along with the compressed data with only the frequency vector encrypted. Since the frequency vector is required for decompression, no further encryption of the compressed data is necessary to secure the compressed file.
H03M 7/30 - Compression; Expansion; Suppression of unnecessary data, e.g. redundancy reduction
H03M 7/40 - Conversion to or from variable length codes, e.g. Shannon-Fano code, Huffman code, Morse code
H03M 7/46 - Conversion to or from run-length codes, i.e. by representing the number of consecutive digits, or groups of digits, of the same kind by a code word and a digit indicative of that kind
37.
IL-2 AND TL1A FUSION PROTEINS AND METHODS OF USE THEREOF
The present disclosure relates to chimeric polypeptides and methods of use thereof. The chimeric polypeptides comprise an interleukin-2 (IL-2) peptide; an immunoglobulin peptide; and a TL1 A peptide. The fusion proteins disclosed herein are a major advance and combine both TL1A (the physiologic ligand of TNFRSF25) and IL-2 (the physiologic ligand of CD25). Such a fusion protein can prolong the half-life of IL-2 and allow lower TLI1 levels. Thus, the inventors generated an !L-2-lgG1-TL1A fusion protein and tested its efficacy in vitro and in vivo. In vitro findings demonstrated that both the TL1A and IL-2 FP subunits were functional.
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
38.
GAIN-SCHEDULING SYSTEM AND METHOD FOR IMPROVING FAN SPEED CONTROL IN AIR HANDLING UNITS
The Board of Regents of the University of Oklahoma (USA)
University of Miami (USA)
Inventor
Wang, Gang
Song, Li
Wang, Zufen
Hurt, Rodney D.
Abstract
The present disclosure describes a system comprising a gain-scheduling control strategy which improves its nonlinear control performance. A control-oriented model, which does not require numerous physical parameters and extensive test data, has been developed to address the nonlinearity of the fan system. Based on theoretical model and experimental verifications, the issue of an aggressive response with a conventional fixed-gain controller is caused by the fact that the system gain is proportional to the ratio of the duct static pressure to the fan speed. To address the issue, a scheduling function of the measurable duct static pressure and fan speed is included in the conventional fixed-gain controller to compensate for the fan system gain variation. The gain-scheduling control strategy approximately maintains the identical control performance under all operation conditions. The gain-scheduling control strategy can be readily implemented on a processor without intensive computation and additional measurements.
F24F 11/77 - Control systems characterised by their outputs; Constructional details thereof for controlling the supply of treated air, e.g. its pressure for controlling air flow rate or air velocity by controlling the speed of ventilators
The present invention provides compositions and methods for detecting components of the inflammasome in a sample from a subject as markers for brain injuries such as multiple sclerosis, stroke or traumatic brain injury. Methods of using such inflammasome markers to determine prognosis, direct treatment and monitor response to treatment for the subject with a brain injury such as multiple sclerosis, stroke, mild cognitive impairment or traumatic brain injury are also described.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
Activation of STimulator of INterferon Genes (STING) triggers cytokine production and facilitates tumor antigen cross-presentation. In an embodiment of the present invention, STING-dependent innate immune signaling pathway activators (STAVs) can be delivered to antigen presenting cells. In various embodiments of the present invention, the STAVs can be delivered in lipid nanoparticle formulations. In various embodiments of the present invention, the range of cancers amenable to STAV therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers Nano-STAVs into the Tumor Micro Environment (TME) to potently generate anti-tumor cytotoxic T cell activity. The STAV formulations can be introduced into solid tumors present in the mammal. Alternatively, the Nano-STAVs can be introduced through direct inoculation. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APC's.
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
The present disclosure relates, in general, to oligonucleotides that stimulate STING (STimulator of Interferon Genes) activity and increase activity of immune cells. The disclosed STING activators (STAVs) are useful in the treatment of cancer and other immune-mediated conditions.
The present disclosure relates to methods of testing immunomodulatory activity of cells, including, for example, mesenchymal stem cells and uses of said cells that are determined as having immunomodulatory activity for treating COVID-19 related acute respiratory distress syndrome (ARDS). Disclosed herein are in vitro methods of evaluating mesenchymal stem cells for their effective immunomodulatory effects in vivo.
Systems and methods for assessing, monitoring, or theranosing a condition or disorder based on a comparison of limb stability for one or more limbs of a subject from a baseline. The method includes placing two or more inertial measurement sensors on the limbs of the subject, acquiring baseline limb excursion data from the inertial measurement sensors while a patient is performing at least one of a static balance activity and a dynamic balance activity by tracking the relative displacement of the respective two or more inertial measurement sensors; acquiring post-injury limb excursion data after an injury from the inertial measurement sensors while a patient is performing at least one of a static balance activity and a dynamic balance activity; and determining the activity clearance index as a function of a comparison of the baseline limb excursion data compared to the post-injury limb excursion data.
Embodiments of an improved photodynamic therapy device are provided. An example of the device includes an irradiation head having a first end and a surface at a second end, the surface having a radius of curvature. The device also includes a plurality of light sources disposed on the curved surface. The plurality of light sources are configured to emit light having at least one wavelength corresponding approximately to an excitation peak of at least one photosensitizer. The light emitted by the plurality of light sources is focused to a focal point based on the radius of curvature of the surface and a target surface (e.g., a corneal surface of an eye) may be positioned at the focal point for treatment.
Systems and methods for an improved dosimeter for measuring dosage for photodynamic therapy treatment are provided. An example systems includes a dosimeter comprising a variable optical filter system configured to receive a second light, the second light comprising luminescence produced by singlet oxygen and one or more background signal and selectively transmit the luminescence and the one or more background signals as a third light, the variable optical filter system comprises a plurality of optical bandpass filters that are switchable to selectively transmit the luminescence and the one or more background signals. The dosimeter also includes a photoreceiver configured to receive the third light and configured to generate electrical output signals corresponding to the luminescence and the one or more background signals, the electrical output signals being indicative of an amount of the singlet oxygen produced based on activating the photosensitizer.
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
Apparatuses and methods for using augmented/mixed reality in surgical settings are provided, and, in particular, apparatuses and methods for intraoperative integration of augmented/mixed reality 3D models with near real-time pathology results. Real-time pathology results are generated using a machine learning analysis of biopsy pathology images in conjunction with a predictive model based on the patient's clinical and demographic data and radiographic imaging data. The apparatuses and methods can be used to provide more accurate intraoperative visualization, tracking, and determination of tumor margins to improve resection extent and any intraoperative or postoperative adjuvant therapy.
The present disclosure relates to methods of silencing expression of genes and uses thereof for treating diseases. Specifically, disclosed herein are Initiation of Transcription GAPmer (INTmers), wherein said INTmers comprise a nucleic acid molecule comprising 14-22 nucleotides, and further wherein said nucleic acid molecule comprises a central core of DNA flanked by RNA on each side.
The disclosure provides a method of predicting the onset of clinical manifestations of amyotrophic lateral sclerosis (ALS) in a human, the method comprising (a) measuring phosphorylated neurofilament heavy chain (pNfH) and/or neurofilament light chain (NfL) levels in a subject, and (b) predicting the onset of ALS, wherein increased levels of pNfH and/or NfL signal the onset of clinical manifestations of ALS.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Devices, systems, and methods for transferring, storing, and/or dispensing a fluid, such as an ocular drug. In one embodiment, a device includes: a first end; and a second end opposite the first end, the first end being configured to be engageable with a secondary reservoir and the second end being configured to release a fluid therefrom. In one embodiment, a method of administering a product includes engaging a secondary reservoir with an engagement assembly at a first end of a device; and delivering a fluid from the secondary reservoir through the engagement assembly and into a chamber of the device to mix with a product within the chamber.
Disclosed herein are methods and compositions related to determining gut transit time. The composition comprises a blue dye, which can be used to measure transit time from consumption to elimination as a waste product.
Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters with biomaterials for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality, are disclosed. Further disclosed are reagents, apparatus, and methods for conformally coating cells and cell clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size.
Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
53.
CANNABIDIOL NANODRUG FORMULATIONS AND METHODS FOR USE OF THE SAME
Disclosed herein are topical formulations of cannabidiol, such as nanoparticulate cannabidiol, methods of making such compositions, and their use in treating autoimmune diseases and disorders, e.g., alopecia areata.
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventor
Mirsaeidi, Mehdi
Zhang, Chongxu
Schally, Andrew V.
Cai, Renzhi
Tian, Runxia
Abstract
The present disclosure is directed to a method of treating an inflammatory disorder, such as sarcoidosis, using a growth hormone-releasing hormone (GHRH) antagonist.
Disclosed herein are Notch transcriptional activation complex kinase (“MACK”) inhibitors, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein include compounds of Formula (Ia) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
Disclosed herein are Notch transcriptional activation complex kinase (“MACK”) inhibitors, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein include compounds of Formula (Ia) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
Systems and devices for temporarily disabling an assailant or other target using disabling flashes of light from a light-emitting device. A tactical lighting system also includes protective eyewear that is paired with the light-emitting device and configured to shutter in synchronization with the pattern of disabling light flashes to protect the wearer’s eyes while disabling an assailant or other target. In one embodiment, the tactical lighting system is modular, with each module being functional independently of the other modules.
The disclosure provides a method of forming carbon dots, including admixing carbon powder with sulfuric acid and nitric acid and heating the carbon powder mixture to reflux to oxidize the carbon powder. The method further includes isolating and purifying the carbon dots. The disclosure further provides applications of the carbon dots for diagnostic analysis (such as bone analysis), fibrillation inhibition, and drug delivery.
A microfluidic structure includes a first media channel or well and a second media channel. A removable membrane is provided between the first media channel or well and the second media channel to permit diffusion. One or more plates is used to form the second media channel. A method of creating a microenvironment using the microfluidic structure is also provided.
Ion booster for thrust generation. The invention pertains to electrical propulsion generated by the rapid acceleration of ions between asymmetrical electrodes. The invention is applicable for propulsion generation in atmospheric and space environments.
Various methods and compositions are provided which can be employed to modulate the immune system. Compositions include a fusion protein comprising: (a) a first polypeptide comprising Interleukin-2 (IL-2) or a functional variant or fragment thereof; and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL-2Rα) or a functional variant or fragment thereof, and wherein the fusion protein has IL-2 activity. Various methods are provided for modulating the immune response in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the IL-2/IL-2Rα fusion protein disclosed herein.
A device, kit, and method for aspirating graft tissue and delivering the graft tissue to a target delivery site. An injector comprises a cylinder and a plunger that is both linearly and rotatably advanceable and retractable within the cylinder. A kit comprises an injector, a cartridge, and a cartridge coupling element that connects the cartridge to the injector. The kit may also include a container that is configured to retain a cartridge and to facilitate connection between the injector and the cartridge. The container includes at least one fluid barrier that prevents spillage of storage solution from the container when the injector is at least partially inserted into the well of the container.
A device, kit, and method for aspirating graft tissue and delivering the graft tissue to a target delivery site. An injector comprises a cylinder and a plunger that is both linearly and rotatably advanceable and retractable within the cylinder. A kit comprises an injector, a cartridge, and a cartridge coupling element that connects the cartridge to the injector. The kit may also include a container that is configured to retain a cartridge and to facilitate connection between the injector and the cartridge. The container includes at least one fluid barrier that prevents spillage of storage solution from the container when the injector is at least partially inserted into the well of the container.
System for combined intraoperative aberrometry and optical coherence tomography (OCT). In an embodiment, the system comprises an OCT system, an aberrometer, a beam delivery system, and a beam splitter. The beam delivery system is configured to output a beam towards a target, wherein the beam has an outward path to the target and a return path after being reflected by the target. The beam splitter is positioned in the return path of the beam and configured to split the return path into a first path to the OCT system and a second path to the aberrometer. Thus, the OCT system and aberrometer can share a single beam delivery system.
An apparatus for vascular access is described herein. The apparatus can comprise a cart movable from a first location to a second location near a patient, a manipulating device configured to releasably couple a cartridge including a needle, a catheter, and a guidewire that are coaxially disposed with respect to each other, and a robotic arm having a first end mounted to the cart and a second end coupled to the manipulating device. The manipulation device can include a plurality of actuation mechanisms configured to selectively advance the needle, the catheter, and the guidewire when the manipulating device is coupled to the cartridge. The robotic arm can include a plurality of joints that are configured to rotate about a plurality of axes to position the cartridge relative to the arm of the patient such that the needle, the catheter, and the guidewire can be inserted into a target vessel of the patient.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A device, kit, and method for aspirating graft tissue and delivering the graft tissue to a target delivery site. An injector comprises a cylinder and a plunger that is both linearly and rotatably advanceable and retractable within the cylinder. A kit comprises an injector, a cartridge, and a cartridge coupling element that connects the cartridge to the injector. The kit may also include a container that is configured to retain a cartridge and to facilitate connection between the injector and the cartridge. The container includes at least one fluid barrier that prevents spillage of storage solution from the container when the injector is at least partially inserted into the well of the container.
A61M 1/00 - Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
67.
Methods for Identifying Modulators of G Protein-Coupled Receptors
The disclosure relates to a plurality of cells, compositions and methods for identifying modulators of a target protein. The cells, compositions and methods comprise a (i) a target domain gene (ii) an intracellular chimeric G-protein alpha subunit comprising an endogenous G-protein alpha subunit with a humanized C-terminus; and (iii) an inducible reporter, wherein the expression of the reporter is dependent on the activation of the target domain encoded by target domain gene, and wherein the target domain gene comprises a barcode. The disclosure further relates to a host cell comprising a plurality of exogenous landing pads integrated in the host cell's genome, wherein each exogenous landing pad is integrated at a safe harbor genome loci in the host cell's genome.
THE TRUSTEES OF THE UNIVERSITY OF PENNYSLVANIA (USA)
UNIVERSITY OF MIAMI (USA)
Inventor
Stelekati, Erietta
Wherry, E. John
Fraietta, Joseph A.
Abstract
The current invention includes compositions and methods comprising immune effector cells modified to express miR-29a for the purpose of resisting immune exhaustion.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
69.
MATERIALS AND METHODS FOR EXTRACELLULAR VESICLE DETECTION
Described herein is a method for detecting the presence of circulating extracellular vesicles in a subject. The method comprises contacting a biological sample from the subject with an antibody mimetic that specifically binds to a cell surface marker on the vesicles, wherein the antibody mimetic is coupled to a detectable label; and detecting presence of extracellular vesicles in the sample by detecting the presence of the detectable label coupled to the antibody mimetic bound to the vesicles.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines. TNFR25 specific immunotoxins disclosed herein are also capable of increasing the effectiveness of a chemotherapeutic regimen by depleting a cancer patient of naturally occurring immunosuppressive cells.
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 35/13 - Tumour cells, irrespective of tissue of origin
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
72.
NANOPARTICLES AND USES THEREOF FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
Bacillus subtilisBacillus subtilis. Also disclosed are methods of preventing or treating a COVID-19 infection comprising providing the SARS-CoV-2 vaccine to a subject.
This disclosure relates to systems, compounds and methods for stem cell delivery. More specifically, the disclosure relates a system for promoting tissue regeneration, the system comprising a plurality of stem cells coated with at least one or a plurality of dendrimer nanocarriers that specifically bind to an adhesion molecule. Additionally, the disclosure relates to methods for delivering stem cells to damaged or diseased tissue for stem cell regeneration of the tissue.
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
STING-dependent innate immune signaling pathway activators (STAVs) are delivered to antigen presenting cells in lipid nanoparticle formulations. The range of cancers amenable to STAV therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers STAV's into the Tumor MicroEnvironment (TME) to potently generate anti-tumor cytotoxic T cell activity. The range of cancers include melanomas and cutaneous T cell lymphomas. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APC's. Alternatively, the lipid nanoparticles can be introduced through direct inoculation.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
STING-dependent innate immune signaling pathway activators (STAVs) are delivered to antigen presenting cells in lipid nanoparticle formulations. The range of cancers amenable to STAV therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers STAV's into the Tumor MicroEnvironment (TME) to potently generate anti-tumor cytotoxic T cell activity. The range of cancers include melanomas and cutaneous T cell lymphomas. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APC's. Alternatively, the lipid nanoparticles can be introduced through direct inoculation.
C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
Ocular photosensitivity analyzer. In an embodiment, a programmable light source, comprising a plurality of multi-spectra light modules, is configured to emit light according to a lighting condition. For one or a plurality of iterations, the programmable light source is activated to emit the light according to the lighting condition, and collect a response, by a subject, to the emitted light via a sensing system comprising one or more sensors. Between iterations, the programmable light source may be reconfigured based on the response to determine a visual photosensitivity threshold of the subject.
This disclosure relates generally to compositions of carbon dots, doxorubicin, and transferrin and methods for use of the same in the treatment of DLBCL tumors.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
Disclosed herein are methods for the treatment of Demodex including the step of contacting the Demodex with 5-fluorouracil, or salt thereof. Disclosed herein are ophthalmic compositions including 5-fluorouracil or salt thereof suitable for the treatment of Demodex.
Antibodies specific for secretogranin III (Scg3) are disclosed. Methods of using the antibodies, antigen-binding fragments thereof, or pharmaceutical compositions comprising the same in the treatment of diseases such as diabetic retinopathy, neovascular age-related macular degeneration, retinopathy of prematurity, and cancer, are also disclosed.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
82.
ENGINEERED MEGANUCLEASES THAT TARGET HUMAN MITOCHONDRIAL GENOMES
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in combination with mitochondrial transit peptides in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been modified or edited.
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.
Additive manufacturing of composites with short-fiber reinforcement. In an embodiment, an extrusion channel is supplied with a composite ink comprising short fibers, and the composite ink is extruded out of a material outlet of the extrusion channel, while vibrating the extrusion channel and the material outlet by one or more vibration motors along one or more vibration axes, to fabricate a three-dimensional composite structure. The short fibers may comprise milled carbon fibers having an average length of 50 μm or less and an average aspect ratio of 4.5 or less, and the composite ink may comprise a high fiber volume ratio (e.g., 27+%). Despite analytical models that predict otherwise, the composite structures, resulting from disclosed embodiments, have enhanced strength.
B33Y 30/00 - ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING - Details thereof or accessories therefor
Provided herein is a process for preparing a nitrate comprising contacting a nitrogen oxide with a metal oxide under milling conditions to form a nitrate.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPT. OF VETERANS AFFAIRS (USA)
Inventor
Weintraub, Neal L.
Romero Lucas, Maritza J.
Lucas, Rudolf
Schally, Andrew
Cai, Renzhi
Abstract
Provided herein are compositions and methods of use thereof for the treatment of metabolic disease such as diabetes and obesity. One embodiment provides a method of treating a metabolic disease or syndrome in a subject in need thereof by administering to the subject a therapeutically effective amount of a growth hormone releasing hormone (GHRH) antagonist or a pharmaceutical composition comprising the GHRH antagonist to reduce triglyceride-rich-lipoproteins (TRL) in the subject to treat the metabolic condition or syndrome.
Quantification of symmetry and repeatability in limb motion for treating abnormal motion patterns. In the context of gait analysis, gait data may be acquired as signals from inertial sensors (e.g., gryoscopes). Each signal represents an angular velocity of a lower limb segment of a subject during ambulation. Each signal may be segmented into stride signals, and a gait metric may be calculated based on the stride signals. The gait metric may comprise a symmetry metric that represents a similarity of the stride signals across two signals acquired for at least one pair of contralateral limb segments. Additionally or alternatively, the gait metric may comprise a repeatability metric that represents a similarity of the stride signals within a signal. In other embodiments, other types of sensors may be used and/or motion data may be acquired and metrics calculated for other types of motions and/or for upper limb segments.
Artificial intelligence for evaluating patient distress using facial emotion recognition. In an embodiment, an artificial intelligence model is applied to facial image(s) of a patient to classify each facial image into one of a plurality of emotional states based on a facial expression in the facial image. A determination may be made as to whether or not to alert a healthcare provider based on the emotional state(s) into which the facial image(s) were classified. If a determination is made to alert a healthcare provider, a notification may be transmitted to the healthcare provider.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G16H 30/00 - ICT specially adapted for the handling or processing of medical images
G06V 40/16 - Human faces, e.g. facial parts, sketches or expressions
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
Device for arterial puncture assistance. In an embodiment, the device comprises an upper component, lower component, and coupling mechanism that couples the lower component to the upper component. The upper component may comprise a platform configured to support a syringe. The lower component may comprise one or more finger holes, wherein each of the one or more finger holes is configured to receive a human finger therethrough, so as to enable contemporaneous stabilization of the lower component on the human finger and palpation of an arterial pulse by the human finger during an arterial puncture.
16 - Paper, cardboard and goods made from these materials
21 - HouseHold or kitchen utensils, containers and materials; glassware; porcelain; earthenware
25 - Clothing; footwear; headgear
41 - Education, entertainment, sporting and cultural services
Goods & Services
Bumper stickers; notebooks; folders for papers; binders;
pens; pencils; decals; printed post cards; blank note cards;
printed note cards; printed posters; paper banners; printed
greeting cards; printed calendars; printed notepads;
stationery; envelopes; stickers; printed general feature
magazines; printed matter, namely, manuals, curricula, and
newsletters, in the field of university level instruction. Cups and mugs; water bottles sold empty; double wall cups;
double wall cups with lids. Shirts; t-shirts; polo shirts; jackets; coats; fleece
pullovers; sweaters; sweatshirts; sweatpants; pants; tank
tops; shorts; headwear, namely, hats, caps and visors. Educational services, namely, providing courses of
instruction at the university level and distribution of
course material in connection therewith.
92.
ELECTROHYDROMODULATING PROCESS FOR RECOVERING NUTRIENTS, MINERALIZING ORGANICS, AND INACTIVATING PATHOGENS IN WASTEWATER
A system for electrohydromodulation of wastewater. In an embodiment, the system comprises an anode in contact with at least one anodic chamber and a cathode in contact with a cathodic chamber. Each anodic chamber and the cathodic chamber are configured to receive a flow of wastewater. A first multivalent cation exchange membrane, between each anodic chamber and the cathodic chamber, allows multivalent cations to pass therethrough while preventing monovalent ions to pass therethrough. A power source is electrically coupled to each anode and the cathode, and is configured to apply a voltage across wastewater in the anodic chamber and the cathodic chamber, to thereby cause multivalent cations in the wastewater to pass through the multivalent cation exchange membrane.
A steerable guide. In an embodiment, the steerable guide comprises a needle, a shaft, a spring housing, and a translational screw. The needle comprises a wire tube and a wire configured to curve the needle when retracted relative to the wire tube. The wire tube is connected to the distal end of the shaft, and the wire is connected to the distal end of the spring housing. The screw extends into a cavity within the shaft, and is configured to move along a longitudinal axis. A spring is positioned within the cavity, between the proximal end of the spring housing and the distal end of the screw. Thus, when the screw moves in the proximal direction while a position of the spring housing is fixed by the wire, the spring is compressed between the proximal end of the spring housing and the distal end of the translational screw.
A61B 90/11 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints
A61B 18/22 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Hand-pieces therefor
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
A61M 25/06 - Body-piercing guide needles or the like
16 - Paper, cardboard and goods made from these materials
21 - HouseHold or kitchen utensils, containers and materials; glassware; porcelain; earthenware
25 - Clothing; footwear; headgear
41 - Education, entertainment, sporting and cultural services
Goods & Services
(1) Bumper stickers; notebooks; folders for papers; binders; pens; pencils; decals; printed post cards; blank note cards; printed note cards; printed posters; paper banners; printed greeting cards; printed calendars; printed notepads; stationery; envelopes; stickers; printed general feature magazines; printed matter, namely, manuals, curricula, and newsletters, in the field of university level instruction.
(2) Cups and mugs; water bottles sold empty; double wall cups; double wall cups with lids.
(3) Shirts; t-shirts; polo shirts; jackets; coats; fleece pullovers; sweaters; sweatshirts; sweatpants; pants; tank tops; shorts; headwear, namely, hats, caps and visors. (1) Educational services, namely, providing courses of instruction at the university level and distribution of course material in connection therewith.
Systems and devices for temporarily disabling an assailant or other target using disabling flashes of light from a light-emitting device. A tactical lighting system also includes protective eyewear that is paired with the light-emitting device and configured to shutter in synchronization with the pattern of disabling light flashes to protect the wearer's eyes while disabling an assailant or other target.
Disclosed herein are inhibitors of the Notch transcriptional activation complex, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein can include compounds of Formula (I) and pharmaceutically acceptable salts thereof: Formula (I), wherein the substituents are as described.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The invention relates to a vector and/or vaccine that can be used for therapeutic and preventive purposes. The virus is based on vesicular stomatitis virus (VSV) with a substituted VSV G (glycoprotein) for HTLV-1 G, referred to as gp62. The vector and/or vaccine further comprise a fusion protein comprising HTLV-1 regulatory proteins (HBZ and TAX) together to make a fusion product (HBZ-TAX) and mutated versions thereof. The vector and/or vaccine do not impede innate immune signaling and generate neutralizing antibodies and CTLs to gp62, HBZ, and TAX.
The disclosure provides a method of treating a polyamine imbalance-related disorder. The method comprises administering phenylbutyrate to a subject in need thereof, thereby treating the polyamine imbalance-related disorder.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
